Trial
NCT00645515
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators
—
Condition
Schizophrenia
Intervention
Ziprasidone
Why stopped
This study was terminated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-21